Clinical trial NCT06939608: Kinetics of Yohimbine in Humans to Explore Sex and CYP2D6 Genotype Interactions
Official title: Kinetics of Yohimbine in Humans to Explore Sex and CYP2D6 Genotype Interactions - YOKI-1 Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Pharmacokinetic Study in Healthy Volunteers
Keywords: sex-specific differences
pharmacokinetics
yohimbine
CYP2D6
genetic polymorphisms
drug metabolism
CYP1A2
¹³C₃-caffeine
Lead sponsor: University Medicine Greifswald
Sponsor class: OTHER
First posted: 2025-04-23
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The study is designed as an open-label, four-arm, parallel assignment, single oral dose protocol, stratifying participants by CYP2D6 genotype (extensive vs. poor metabolizers) and biological sex (women vs. men).
Primary purpose: BASIC_SCIENCE

Brief summary: This study investigates the pharmacokinetics of yohimbine in women and men aged 18 to 40 years to explore sex-specific differences in CYP2D6-dependent drug metabolism. Participants will be classified by their CYP2D6 genotype into extensive metabolizers (EM) and poor metabolizers (PM), forming four distinct study arms:

Arm 1) Women, Poor Metabolizers (PM) n=13 Arm 2) Women, Extensive Metabolizers (EM) n=5 Arm 3) Men, Poor Metabolizers (PM) n=13 Arm 4) Men, Extensive Metabolizers (EM) n=5

Each study arm will receive a single oral dose of 50 µg yohimbine (2 x 1 tablets, 25 µg per tablet) and 25 mg of ¹³C₃-caffeine co-administered as a drinking solution.

The purpose of this study is:

1. To characterize the pharmacokinetics of yohimbine following a single oral dose in women and men across different CYP2D6 phenotypes.
2. To evaluate yohimbine's suitability as a reliable probe for assessing CYP2D6 activity.
3. To investigate potential interactions between CYP2D6 and CYP1A2, as well as interindividual variability in CYP1A2-dependent caffeine metabolism.

Detailed description: The study is designed as an open-label, single-dose protocol with four study arms based on sex and CYP2D6 genotype. A single oral dose of yohimbine and ¹³C₃-caffeine will be administered with 240 ml of still water under overnight fasting conditions.

A total of 19 blood samples will be collected at defined time points (baseline; 10; 20; 30; 40; 50; 60; 70; 80; 90; 100; 110 min; 2; 3; 4; 6; 8; 10; 24 h). At each time point, 4.9 mL of blood will be drawn for plasma separation to determine yohimbine, the primary metabolite 11-OH-yohimbine and 13C₃-caffeine with associated CYP1A2 dependent metabolites. One additional blood sample (EDTA tube) for potential future genetic analysis, will be collected together with the baseline kinetic samples.

For each participant, a total of approximately 98 mL of blood will be collected during the kinetic visits and an additional 12 mL during the screening visit.

Following the administration of yohimbine and 13C3-caffeine, participants will consume 200 mL of sparkling water every hour to stimulate gastrointestinal peristalsis facilitate substance transport. Two hours post-administration, participants may have a cup of tea or coffee, while a standardized meal will be served four hours after dosing.

Urine samples will be collected over 24 hours in three intervals (0-4 h, 5-10 h, 11-24 h). Blood pressure and heart rate monitoring will be conducted during the initial four hours and participants will remain in the Clinical Research Unit of the Institute of Pharmacology for the first 10 hours post-administration. At 24 hours post-dosing, participants will return to the Clinical Research Unit for the final scheduled blood collection and to provide their last urine sample (11-24 h).

Eligibility criteria: Inclusion Criteria:

1. individuals of both biological sexes, assigned as women or men at birth
2. age: ≥ 18 and ≤ 40 years
3. possesses the ability to understand the study purpose and design
4. contractually capable and provides signed informed consent form
5. in good general health or with mild and/or well-managed conditions such as allergies, asthma, hypertension or orthopedic diseases
6. taking no more than three chronic medications
7. individuals classified as either extensive metabolizers (EM) or poor metabolizers (PM) based on their CYP2D6 genotype:

Extensive Metabolizers (EM):

homozygous for CYP2D6 \*1,CYP2D6 \*2, CYP2D6 \*35, or heterozygous combination of any of these alleles

Poor Metabolizers (PM):

homozygous for CYP2D6 \*3, CYP2D6 \*4, CYP2D6 \*5, CYP2D6 \*6, or heterozygous combination of any of these alleles

Exclusion Criteria:

1. BMI \> 30 kg/m2 and \< 18 kg/m2
2. body weight \< 48 kg
3. women: known pregnancy or lactation period; positive urine pregnancy test at screening or kinetic visit
4. men: hemoglobin \< 13 g/dl (8,07 mmol/l) women: hemoglobin \< 12 g/dl (7,45 mmol/l)
5. elevated liver function tests (1 or more of ALAT, ASAT, yGT, Bilirubin \> 2x ULN)
6. reduced renal function (eGFRMDRD \< 60 mL/min/1,7 m2)
7. QTcF \> 450 ms in screening ECG
8. current or recent psychiatric disorders requiring treatment including depression, bipolar disorder, schizophrenia, psychosis or severe anxiety disorders
9. drug dependency at the time of visit
10. use of recreational drugs more than twice a week
11. any known hypersensitivity or allergic reactions to yohimbine or caffeine
12. history of severe hypersensitivity reactions and/or anaphylaxis
13. poor venous conditions that make it impossible to place a peripheral venous catheter and regularly draw blood through it

o) intake of drugs interfering with CYP2D6 and/or CYP1A2 during the past seven days p) intake of yohimbine within 48 hours and caffeine within 16 hours prior to study participation q) engagement in extreme physical activity within 48 hours prior to study participation

Primary outcomes:
measure: Yohimbine plasma concentration expressed as area under the curve (AUC₀-₂₄h) - arm 1 vs. arm 3
timeFrame: 24 hours
measure: Yohimbine plasma concentration expressed as area under the curve (AUC₀-₂₄h) - arm 1 vs. arm 2
timeFrame: 24 hours
measure: Yohimbine plasma concentration expressed as area under the curve (AUC₀-₂₄h) - arm 3 vs. arm 4
timeFrame: 24 hours
Secondary outcomes:
measure: Cmax of yohimbine and 11-OH-yohimbine
timeFrame: 24 hours
measure: tmax of yohimbine and 11-OH-yohimbine
timeFrame: 24 hours
measure: Clearance of yohimbine and 11-OH-yohimbine
timeFrame: 24 hours
measure: Apparent volume of distribution of yohimbine and 11-OH-yohimbine
timeFrame: 24 hours
measure: 11-OH-Yohimbine plasma concentration expressed as area under the curve (AUC₀-₂₄h)
timeFrame: 24 hours
Other outcomes:
measure: Cmax of ¹³C₃-caffeine and paraxanthine
timeFrame: 24 hours
measure: tmax of ¹³C₃-caffeine and paraxanthine
timeFrame: 24 hours
measure: ¹³C₃-caffeine and paraxanthine plasma concentrations expressed as area under the curve (AUC₀-₂₄h)
timeFrame: 24 hours
measure: Renal clearance of ¹³C₃-caffeine and paraxanthine
timeFrame: 24 hours
measure: Apparent volume of distribution of ¹³C₃-caffeine and paraxanthine
timeFrame: 24 hours
Locations:
city: Greifswald
country: Germany
facility: University Medicine Greifswald, Institute of Pharmacology
state: Mecklenburg-Vorpommern
Study officials:
References: